Clinical trial • Phase I • Oncology

PF-08052667 for Non-muscle invasive bladder cancer

Phase I trial of PF-08052667 for Non-muscle invasive bladder cancer. 200 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Non-muscle invasive bladder cancer
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
23-10-2025
First CTIS Authorization Date
02-03-2026

Trial design

Phase I trial across 5 sites in France, Spain.

Target Sample Size
200
Trial Duration For Participant
2418

Eligibility

Recruits 200 Vulnerable population not selected; no special consent or assent handling described in the CTIS record..

Vulnerable Population
Vulnerable population not selected; no special consent or assent handling described in the CTIS record.

Recruitment

Planned Sample Size
200
Recruitment Window Months
79
Consent Approach
No informed consent or assent process details provided in the CTIS record.

Geography

Total Number Of Sites
5
Total Number Of Participants
22

France

Earliest CTIS Part Ii Submission Date
15-12-2025
Latest Decision Or Authorization Date
02-03-2026
Processing Time Days
77
Number Of Sites
2
Number Of Participants
11

Sites

Site Name
Assistance Publique Hopitaux De Paris
Department Name
Urologie
Principal Investigator Name
Morgan Roupret
Contact Person Name
Morgan Roupret
Contact Person Email
mroupret@gmail.com
Site Name
Institut Gustave Roussy
Department Name
Oncology
Principal Investigator Name
Yohann Loriot
Contact Person Name
Yohann Loriot
Contact Person Email
yohann.loriot@gustaveroussy.fr

Spain

Earliest CTIS Part Ii Submission Date
15-01-2026
Latest Decision Or Authorization Date
02-03-2026
Processing Time Days
46
Number Of Sites
3
Number Of Participants
11

Sites

Site Name
Hospital Universitario 12 De Octubre
Department Name
Oncologia
Principal Investigator Name
Felix Guerrero-Ramos
Contact Person Name
Felix Guerrero-Ramos
Contact Person Email
francabreraruiz@gmail.com
Site Name
Hospital De La Santa Creu I Sant Pau
Department Name
oftalmologia & oncologia
Principal Investigator Name
Oscar Rodriguez Faba
Contact Person Name
Oscar Rodriguez Faba
Site Name
Fundacio Puigvert
Department Name
Oncologia
Principal Investigator Name
Oscar Rodriguez Faba
Contact Person Name
Oscar Rodriguez Faba

Sponsor

Primary sponsor

Full Name
Pfizer Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Investigational products

Investigational Product Name
PF-08052667

Related trials

Other published trials that may interest you.